This panel addresses AMR as a critical threat to patients’ lives and the future of modern medicine. Moving beyond awareness, it focuses on actionable steps to drive innovation, boost the weak antibiotic pipeline, and establish sustainable access through effective push and pull incentives. The discussion will highlight antibiotics’ role as life-saving enablers, their economic value, and the urgent need to recognize their contribution across disease areas. It will also explore Big Pharma’s role, private investment strategies, and how to build a sustainable innovation ecosystem focused around Biotech start-ups. Finally, the panel will consider how Switzerland and international stakeholders can operationalize the recent UNGA declaration, turning global commitments into measurable progress.
May 5, 16:30-17:15, room Marriott 3+4+5
| Name | Position | Institution |
|---|---|---|
| Guillermo Tramontin | Associate Partner | Cavenagh Health |
| Name | Position | Institution |
|---|---|---|
| Najy Alsayed | Global Therapeutic Area Head - Infectious Diseases | Menarini Group |
| Damiano de Felice | Chief of External Affairs | CARB-X |
| Deepali Patel | Director, International Policy | AMR Action Fund |
| Marc Gitzinger | CEO and Founder | BioVersys |
The Menarini Pharmaceutical Group, headquartered in Florence, operates in 140 countries with €4.38 billion in turnover and over 18,000 employees. It has 9 R&D centers and 18 manufacturing plants in Italy and abroad, producing over 609 million medicine packs annually. Its portfolio spans cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and analgesic therapies. Menarini’s high-quality production supports patient health worldwide.
Cavenagh Health is a specialist life sciences talent partner dedicated to building high-performing teams for early-stage biotech and health technology companies. Collaborating with over 200 life science global investors and industry leaders, we accelerate meaningful transformation in healthcare through frontier science and technology. Trusted by pioneering therapeutic and health technology organizations worldwide, we provide tailored talent strategies that realize milestones, empower innovation, and ultimately improve patient outcomes. Our expertise spans the UK, Europe, and the US, supporting ventures from securing funding to achieving their patient goals.
